
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Susan Cornell, PharmD, CDE, FAPhA, FAADE, outlines some strategies for pharmacists tasked with selecting the most appropriate second-line therapy for their patients with type 2 diabetes.
Susan Cornell, PharmD, CDE, FAPhA, FAADE, outlines some strategies for pharmacists tasked with selecting the most appropriate second-line therapy for their patients with type 2 diabetes.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.






